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Laboratory animals have long since been used extensively in bioassays for prions in 2 
order to quantify, usually in terms of median infective doses [ID50], how infectious 3 
these pathogens are in vivo. The identification of aberrant prion protein as the main 4 
component and self-replicating principle of prions has given rise to alternative 5 
approaches for prion titration. Such approaches often use protein misfolding cyclic 6 
amplification (PMCA) for the cell-free biochemical measurement of prion-associated 7 
seeding activity, or cell assays for the titration of in vitro infectivity. However, median 8 
seeding- and cell culture infective doses ([SD50 and CCID50, respectively]) of prions 9 
are neither formally congruent nor definitely representative for ID50 titers in animals 10 
and can be therefore only tentatively translated into the latter. This may potentially 11 
impede the acceptance and use of alternative methods to animal bioassays in prion 12 
research. Thus, we suggest to perform PMCA- and cell assays jointly, and to check 13 
whether these profoundly different test principles deliver consistent results in order to 14 
strengthen the reliability and credibility of prion ID50 assessments by in vitro methods. 15 
With regard to this rationale, we describe three pairs of PMCA- and glial cell assays 16 
for different hamster-adapted prion agents (the frequently used 263K scrapie strain, 17 
and 22A-H scrapie and BSE-H). In addition, we report on the adaptation of 18 
quantitative PMCA to human vCJD prions on steel wires for prion disinfection 19 
studies. Our rationale and methodology can be systematically extended to other 20 
types of prions and used to further reduce or replace prion bioassays in rodents. 21 
  22 
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For decades, research into prions and the diseases they cause in animals and 23 
humans (e. g. scrapie, bovine spongiform encephalopathy [BSE], sporadic or variant 24 
Creutzfeldt-Jakob disease [sCJD or vCJD, respectively]) was largely dependent on 25 
animal experiments.1 Only with the gradually unfolding molecular nature of prions, 26 
and the identification of aberrant prion protein (PrP) as their main component,1,2 it 27 
has become possible to get a handle on these pathogens also in vitro. Hence, a 28 
variety of biochemical methods that use pathological prion protein as molecular 29 
surrogate marker for the qualitative or semi-quantitative detection of prions has been 30 
established during the past few years.2,3  31 
However, a direct appraisal of how infective prions are in vivo can still be done only 32 
by inoculation of sample material into animals and incubation time interval assays or 33 
end-point titrations.4 Both approaches rely on the transmission of a prion infection 34 
that eventually becomes evident by the onset of neurological symptoms. In contrast, 35 
the qualitative and quantitative detection of prion infectivity in vitro has become 36 
gradually feasible by cell culture approaches.5 Yet, so far there are only few cell 37 
assays available for this purpose, and their applicability is generally restricted 38 
because they mostly work with just one or few of the multiple prion strains known to 39 
exist under laboratory and real-life conditions. Thus, animal bioassays are still being 40 
frequently used in prion research. 41 
Prions consist essentially of an isoform of the host-encoded prion protein with a 42 
pathological, β-sheet rich folding- and aggregation structure.1,6 Such prion-forming 43 
conformers of PrP are referred to as PrPSc or PrPTSE (“Sc” and “TSE” are acronyms 44 
for “scrapie” , and “transmissible spongiform encephalopathy”, respectively, with the 45 
latter being an alternative name for prion diseases).1,7 The replication of prions is 46 
thought to be mediated by a process that basically resembles the seeded growth of 47 
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crystals. In this process, designated as nucleation-dependent polymerization,8,9  48 
oligomers or polymers of PrPTSE act as nuclei (“seeds”) that recruit cellular prion 49 
protein (PrPC) and incorporate it, in a misfolded form, into their growing amyloid-like 50 
aggregate structure. When PrPTSE aggregates break up into smaller units this leads 51 
to a multiplication of PrP particles with proteinaceous seeding activity and thereby 52 
causes further autocatalytic replication of the pathological protein state. According to 53 
this concept, prions are proteinaceous infectious particles whose self-replication is 54 
mediated by biochemical seeding activity, i. e. the property to convert normal 55 
protease-sensitive PrPC into misfolded, aggregated and usually Proteinase K-56 
resistant prion protein (PrPres). 57 
Despite the great importance of animal bioassays in prion research they are time-58 
consuming, expensive, rather restricted in throughput and potentially critical in both 59 
regulatory and ethical respect. Therefore, substantial efforts have been made in 60 
search for alternative methods that would allow a reliable quantification of prion 61 
infectivity with reduced or no need for animal experiments. Additionally to cell 62 
assays,10-12 such methods use cell-free biochemical approaches for the quantitative 63 
measurement of prion-associated seeding activity.13-15 64 
  65 
Cell-based assays for the titration of prion infectivity: Due to substantial 66 
methodological advancements it has become possible to titrate the infectivity of 67 
certain murine scrapie prions (22L, RML) in quantitative cell-based assays using 68 
subcloned neuroblastoma (N2a) cells.10-12 Furthermore, RK13 cells transgenically 69 
expressing PrP from mouse, sheep or cervids were shown to allow the titration of 70 
RML prions,16 a natural sheep scrapie isolate (PG127),16 and chronic wasting 71 
disease agent,17 respectively.  72 
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Biochemical assays for the measurement of prion-associated seeding activity: 73 
Prion replication by seeded PrP polymerization implicates the seeding activity of 74 
PrPTSE as an essential biochemical counterpart of biological prion infectivity. 75 
However, prion-associated seeding activity that transforms normal protease-sensitive 76 
PrPC into pathological and usually Proteinase K-resistant prion protein (PrPres) has 77 
become amenable to sensitive biochemical monitoring only by the introduction of 78 
protein misfolding cyclic amplification (PMCA) in the year 2001.18 PMCA is a cyclic 79 
process that mimics, in an accelerated mode, nucleation-dependent PrP 80 
polymerization in the test tube. PMCA cycles basically consist of two phases. In the 81 
first phase, PrP seeds such as PrPTSE from animals or humans are incubated in 82 
normal brain homogenate containing an excess of PrPC to induce the growth of PrP 83 
oligomers or polymers. In the second phase, the sample is exposed to ultrasound. 84 
The ultrasonic treatment fragments grown PrP aggregates into smaller units, which in 85 
turn provides new seeding-active particles for further aggregate growth. Thus, with 86 
each PMCA cycle the number of seeds increases and accelerates the replication of 87 
the pathological protein state.19 This effect may be enhanced by “serial PMCA” in 88 
which reaction mixtures are periodically passaged into fresh normal brain 89 
homogenate after a certain number of PMCA cycles.20,21 Several different technical 90 
advancements of the PMCA technology, called quantitative PMCA and real-time 91 
quaking induced conversion assay (RT-QuIC) now allow the direct titration of prion 92 
seeding activity in vitro.13-15,22  93 
The introduction of PMCA and RT-QuIC was performed with hamster-adapted 263K 94 
scrapie agent that has long since been used as a laboratory prion strain for many 95 
purposes of basic and applied TSE research.13,14,18 When the biological infectivity 96 
and biochemical seeding activity of 263K scrapie prions in different sample materials 97 
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were systematically compared, this empirically confirmed a consistent quantitative 98 
correlation between the biological infectivity and biochemical seeding activity.14,15 99 
 100 
Rationale for the further reduction and replacement of prion titrations in 101 
animals by quantitative cell- and PMCA assays: Quantitative prion bioassays in 102 
animals usually determine infectivity titres in terms of the median infective doses 103 
(ID50) that had been present in the inoculated sample material. One prion ID50 is the 104 
dose of prions that causes infection in 50% of inoculated animals. If such in vivo 105 
titration is to be reproduced in vitro this may be achieved best by a simultaneous 106 
titration of the median PMCA seeding dose (SD50) and the median cell culture 107 
infective dose (CCID50) in the test sample. In this context, one SD50 is the dose of 108 
seeding activity that converts PrPC into PrPres in 50% of PMCA samples, and one 109 
CCID50 is the dose of prions that causes infection (in terms of PrPres propagation) in 110 
50% of inoculated cell cultures. Formally, neither SD50 nor CCID50 are congruent to 111 
ID50, and the reliability of PMCA- and cell assays in terms of a correct ID50 112 
determination cannot be taken for granted. However, based on empirically 113 
established quantitative correlations between SD50, CCID50 and ID50 in reference 114 
standards such as homogenized 263K scrapie hamster brain tissue (in the following 115 
referred to as “263K stock”), SD50- and CCID50 values detected in test samples can 116 
be tentatively translated into ID50 values. PMCA- and cell assays represent 117 
profoundly different cell-free and cell-based test principles for the biochemical and 118 
biological titration, respectively, of prion activity in vitro. Therefore, if these assays 119 
independently deliver consistent ID50 assessments, this substantially backs up the 120 
overall test reliability as compared to titrations based on either PMCA- or cell assays 121 
alone. Such internal consistency checks may mitigate reservations as to the reliability 122 
of in vitro alternatives to animal bioassays and thereby promote their acceptance and 123 
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use in prion research. Accordingly, we suggest an integrated approach for the 124 
reduction and replacement of prion bioassay titrations in animals that includes both 125 
the measurement of seeding activity and the determination of cell culture infectivity 126 
by quantitative, sensitive and robust PMCA- and cell assays, respectively.    127 
With regard to this rationale, we here report on recent progress of our laboratory in 128 
the further development of PMCA- and cell assays for different prion agents. Our 129 
present work builds on in vitro assays previously established by us for the qualitative 130 
biological detection of prion infectivity in glial cell cultures and the biochemical 131 
measurement of prion seeding activity by quantitative PMCA.15 Firstly, we describe a 132 
glial cell assay that can be used for the quantitative biological titration of 263K 133 
scrapie infectivity in vitro, and its amendment by a simple quantitative PMCA assay 134 
for this prion strain. Secondly, we outline the adaptation of PMCA- and cell assays to 135 
other hamster-adapted scrapie- or BSE agents. Finally, we present a quantitative 136 
PMCA assay for human vCJD prions on steel wires that can be used in prion 137 
disinfection studies.  138 
 139 
Animals, materials and methods 140 
Prion agents from animals and humans 141 
Hamster-adapted prion agents 263K scrapie, 22A-H scrapie and BSE-H were taken 142 
from brain sample stocks of our laboratory. These materials had been produced in 143 
previous studies by intracerebral inoculation, under Ketavet/Rompun anesthesia, of 144 
outbred Syrian hamsters (mesocricetus auratus; strain: LVG Golden Syrian Hamster; 145 
Charles River, Sulzfeld, Germany) with hamster brain homogenates from clinically 146 
diseased donors as previously described.23 These studies were performed in strict 147 
accordance with the European Convention for the Protection of Vertebrate Animals 148 
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used for Experimental and other Scientific Purposes and the German Animal Welfare 149 
Act (Tierschutzgesetz). The protocols were reviewed and approved by the 150 
responsible Committee on the Ethics of Animal Experiments (“Tierversuchs-151 
kommission – Berlin”) affiliated at the Authority for Animal Protection in Berlin 152 
(“Landesamt für Gesundheit und Soziales Berlin”, Berlin, Germany; 153 
http://www.lageso.berlin.de; Permit Number G0085/00). Prion-infected hamsters had 154 
been regularly observed for clinical symptoms and were humanely euthanized by 155 
inhalation of CO2 upon the development of prion disease.  156 
Human vCJD brain tissue (10% [w/v] homogenate in 0.25 M sucrose, reference code 157 
NHBY0/0003, in the following text referred to as “vCJD stock”) was kindly provided 158 
by the National Institute for Biological Standards and Control (Potters Bar, UK).  159 
   160 
Use of normal hamsters and mice 161 
Normal Syrian hamsters (for strain and supplier see above) were used as donors of 162 
brain tissue for the preparation of PrPC-containing substrate for PMCA of hamster-163 
adapted prions and euthanized by exposure to CO2.  164 
Brains from normal mice (species: mus musculus; strain: 129; substrain: 129/Ola; 165 
transgene HuMM) transgenically expressing human prion protein homzygous for 166 
methionine at position 129 of the human PrP gene used to prepare the substrate for 167 
PMCA with vCJD prions were developed and kindly provided by the group of Jean 168 
Manson (Neurobiology Division of the Roslin Institute, University of Edinburgh, 169 
Edinburgh, UK).24  170 
For the preparation of glial cell cultures, normal neonatal Syrian hamsters (for strain 171 
and supplier see above) were used as donors of brain tissue and sacrificed 2-3 days 172 
after birth by decapitation.15     173 
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Although not mandatory, we reported euthanasia of Syrian hamsters to the animal 174 
protection authority (Landesamt für Gesundheit und Soziales Berlin, Berlin, 175 
Germany; Registration Number T0220/07). 176 
 177 
Preparation of brain homogenates 178 
Brain homogenates from Prion-infected hamsters, normal hamsters and normal 179 
HuMM-mice were prepared using previously published procedures.15 Tissue 180 
homogenizations were performed in phosphate buffered saline (PBS, pH 7.4) or 181 
conversion buffer (CB) for cell- or PMCA assays, respectively.   182 
  183 
Glial cell assays  184 
Glial cell cultures used for the detection of 263K scrapie infectivity were prepared in 185 
culture flasks, infected and analysed as described previously.15 For infection, these 186 
cultures were exposed to 1.0x10-7 g or 1.0x10-8 g 263K stock. All other cell assays 187 
were based on the protocol by Pritzkow et al. with modifications for the cryo-storage 188 
of cells and their cultivation in 6-well plates.15  189 
 190 
Cryo-storage of glial cells  191 
For cryo-storage, 3x106 cells were diluted in 1 ml 70 % (v/v) Dulbecco´s modified 192 
Eagle medium (DMEM) containing 20 % (v/v) fetal calf serum (FCS), and 10 % (v/v) 193 
dimethyl sulfoxide (DMSO) per cryo-vial. Vials were cooled down overnight to -70 °C 194 
using a freezing container with a cooling rate of -1 °C/min. The next day, cryo-vials 195 






Plate cultivation, infection, harvesting and analysis of glial cell cultures 200 
After quick thawing of a cryo-vial cells (1 ml) were washed with 9 ml growth medium 201 
(GM), resuspended, mechanically separated, and cultivated for two days in 3 ml GM 202 
at a density of 1.5x104 cells/per well in 6-well plates (8.96 cm2/well, TPP, 203 
Trasadingen, Switzerland). 204 
Cell cultures were exposed to 1.0x10-3 g, 1.0x10-4 g or 1.0x10-5 g BSE-H hamster 205 
brain tissue (“BSE-H stock”), or to 1.0x10-5 g 22A-H scrapie hamster brain tissue 206 
(“22A-H stock”), respectively, per plate well. Cultures for negative controls were 207 
exposed to 1.0x10-3 g normal hamster brain tissue . After three days of cultivation, 208 
the inoculum was removed and the cells were washed once with PBS.  209 
Cultures were harvested at the indicated time points (3, 40, 42, 80, 100 or 122 days 210 
post initial exposure [DPE]). After washing with PBS, cells were detached with a cell 211 
scraper and collected in 1 ml PBS. Cells were pelleted by quick spin and 212 
resuspended in 50 μl PBS containing 1% (v/v) n-lauroylsarcosine (sarcosyl). 213 
Subsequent processing and analysis of harvested cells was performed as described 214 
previously,15 and the Spearman-Kärber method was used for CCID50 titration.
25 The 215 
standard deviation of 263K CCID50 titration was determined on the basis of individual 216 
Spearman-Kärber analyses with four different sample sets. 217 
 218 
Protein misfolding cyclic amplification 219 
PMCA with hamster-adapted prions 220 
PMCA with hamster-adapted prions was performed using a previously described 221 
procedure with specific adaptations.15 In brief:  222 
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10 µl samples of 10 % (w/v) normal brain homogenate in conversion buffer  223 
containing 10-9, 10-10, 10-11 or 10-12 g 263K stock, 10-5 or 10-6 g 22A-H stock, or 10-5 224 
or 10-6 g BSE-H stock, were mixed with 140 μl of 10 % (w/v) normal brain 225 
homogenate in conversion buffer  and glass beads, and subjected to PMCA. 226 
Approximately 30 μl (10 mg) of glass beads (diameter 0.5-0.75 mm; Roth, Germany) 227 
were filled into each reaction tube for PMCA with 263K, 22A-H and BSH-H. One 228 
PMCA round originally consisted of 24 cycles of 40-second sonications (190-220 W) 229 
followed by 1 hour incubation at 37 °C.  230 
However, for PMCA with 22A- or BSE-H the following protocol modifications were 231 
applied as well: The concentration of ethylenediaminetetraacetic acid (EDTA) in 232 
PMCA batches was increased to 20 mM, and one round of PMCA was adjusted to 12 233 
cycles consisting of 40-second sonications followed by 2 hours incubation at 37 °C 234 
for BSE-H, and 4 hours incubation for 22A-H, respectively.   235 
30 l aliquots from PMCA-batches collected prior to PMCA, or obtained after each 236 
round of PMCA, were processed and analysed as previously described.15 SD50 237 
titration of 263K stock was performed by using the method of Spearman-Kärber as 238 
previously described in the context of RT-QuIC.14,25 The standard deviation of 263K 239 
SD50 titration was determined on the basis of individual Spearman-Kärber analyses 240 
with 10 different sample sets. 241 
 242 
PMCA with human vCJD prions on steel wires 243 
The contamination with vCJD prions and PMCA processing of stainless steel wires 244 
was performed as described elsewhere with modifications:15 For contamination, 245 
batches of 30 stainless steel wires (diameter 0.25 mm, length 5 mm) were incubated 246 
in 150 μl each of 10-2, 10-3, 10-4, 10-5, 10-6-diluted vCJD brain homogenate (vCJD 247 
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stock) for 2 h. A 10 % (w/v) brain homogenate from HuMM-mice in PBS was used to 248 
similarly contaminate negative control wires, and as diluent for vCJD stock. Batches 249 
of 15 wires were subjected to PMCA in 150 μl 10 % (w/v) HuMM-mouse normal brain 250 
homogenate in conversion buffer as PrPC substrate. A total of nine serial PMCA 251 
rounds was performed. Each round consisted of 24 cycles of 40 seconds sonication 252 
(~ 210 W) followed by 1 hour incubation at 37°C. Upon completion of a PMCA round 253 
75 µl of reaction mixtures were harvested and transferred into new reaction vials 254 
containing 75 µl of fresh 10 % (w/v) HuMM-mouse normal brain homogenate in 255 
conversion buffer  and 30 μl glass beads. 15 μl aliquots from PMCA-batches 256 
collected after each round of PMCA were subjected to PK digestion at 75 µg/ml PK 257 
and 55°C for 45 min for SDS-PAGE and Western blotting.  258 
 259 
SDS-PAGE and Western blotting 260 
SDS-PAGE and Western blotting using the monoclonal anti-PrP antibody 3F4 for the 261 
detection of hamster- and human PrP,26 and the preparation of PrPres blot standards 262 
for Western blot analyses were performed as described elsewhere.27  263 
 264 
Results 265 
Quantitative cell assay for the titration of 263K scrapie infectivity in vitro 266 
As we reported recently,15 primary glial cell cultures from Syrian hamsters can be 267 
infected with the 263K scrapie agent. Upon exposure to 263K scrapie prions such 268 
glial cell cultures showed an accumulation of seeding active PrPres. When we 269 
established this cell assay in a previous study, we observed that an inoculation with 270 
2.5x10-5 g 263K stock resulted in a higher amount of detectable PrPres at 40 days 271 
post initial exposure (DPE) than an inoculation with only 1.0x10-6 g 263K stock.15 272 
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These findings prompted us to examine whether the glial cell assay exhibits a 273 
consistent dependency of PrPres formation from the infective dose in the inoculum. 274 
Therefore, we exposed cell cultures in the present study to lower amounts of 275 
infectivity. 276 
Representative results from our previous analyses with 2.5x10-5 and 1.0x10-6 g 263K 277 
stock,15 and from the cell assay now performed with 1.0x10-7 and 1.0x10-8 g 263K 278 
stock, are displayed in Figure 1 (PrPres staining found at 3 DPE for 2.5x10-5 g 263K 279 
stock probably originated from original inoculum that could not be washed off the 280 
cells). Aliquots each representing 3.8 μl of resuspended cell culture pellets were 281 
loaded onto the gels for Western blotting. We did not perform a normalization of the 282 
loaded material in terms of cell numbers or protein markers (e. g. actin) because the 283 
amount of cellular material in the cultures increased with the time period of cultivation 284 
(not shown). Thus, such normalization would have required a dilution of samples 285 
harvested at 40 DPE (or later) and thereby impaired the sensitivity of the assay.   286 
PrPres accumulation, i. e. infection, was detected in all, 50% or none of the cell 287 
cultures challenged with 2.5x10-5g (n=4) or 1.0x10-6 g (n=4), 1.0x10-7 g (n=4), or 288 
1.0x10-8 g (n=4) 263K stock, respectively. A titre analysis of these results performed 289 
in analogy to the method of Spearman-Kärber revealed that 1.0x10-7.0 g (standard 290 
deviation: 0.6 logarithmic10 units) of the 263K stock (from previous titrations in 291 
hamster bioassays known to carry about 1x102 intracerebral ID50) contained one 292 
CCID50 in the cell assay performed with a cultivation period of 40 DPE.
25,28  293 
Based on these results our cell assay can be used for the quantification of unknown 294 
infectivity titres in 263K scrapie samples by a simple standard procedure:  295 
Test cell cultures are inoculated, at least in duplicate, with aliquots of serially tenfold 296 
100 – 10-8-diluted samples of unknown 263K scrapie material. In parallel, reference 297 
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cell cultures are similarly challenged with serial tenfold dilutions of 263K stock 298 
containing 1.0x10-6, 1.0x10-7 or 1.0x10-8 g 263K brain tissue (such internal assay 299 
calibration is required because the efficiency of PrPres production in infected cell 300 
cultures may theoretically vary between different assay batches). The dilutions of the 301 
unknown test material and of the 263K stock containing one CCID50 each are 302 
determined from the cell culture read-outs by the method of Spearman-Kärber. On 303 
this basis, the concentration of cell culture infectivity in the test material can be 304 
calculated and directly compared to the cell culture infectivity of the 263K stock. By 305 
using the correlation factor between CCID50 and ID50 of the 263K stock, cell culture 306 
infectivities of test samples are finally tentatively translated into ID50 values.   307 
 308 
Cryo-storage and plate cultivation of glia   309 
Our modified cell culture protocol allows the cryo-storage of ready-to-use glia for at 310 
least 6 months and their cultivation in six well plates. Due to these modifications glia 311 
isolated from a normal hamster brain are sufficient to produce about 300 individual 312 
glial cultures of 1.5x104 cells per well.     313 
 314 
Cell assays for other hamster-adapted scrapie- and BSE agents 315 
In previous bioassay studies, 263K scrapie-, 22A-H scrapie- and BSE-H prions 316 
caused clinically fully developed prion diseases in Syrian hamsters at 83±5, 206±8 317 
and 287±28 days, respectively.23 Despite the substantially prolonged incubation 318 
times of 22A-H- and BSE-H prions as compared to 263K prions in the hamster 319 
bioassay, glial cell cultures could be infected by both of these agents (Figure 2). The 320 
efficiency of infection seemed to be similar for 263K- and 22A-H scrapie after a 321 
challenge with 2.5x10-5 or 1.0x10-5 g 263K- or 22A-H stock, respectively (Figure 2A). 322 
In contrast, 1.0x10-5 g and 1.0x10-4 g BSE-H stock failed to produce detectable 323 
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infection of glial cultures at 42 DPE (Figure 2B). Therefore, we kept the glial cultures 324 
for longer cultivation periods of 100 and 122 days after exposure to BSE-H. Under 325 
these conditions, again, no cell culture infection could be detected after challenge 326 
with 1.0x10-5 g BSE-H stock. However, glial cells showed a dose-dependent PrPres 327 
accumulation at 100 and 122 DPE after exposure to 1.0x10-4 or 1.0x10-3 g BSE-H 328 
stock (Figure 2B). This indicated a lower sensitivity and highlighted the need for 329 
prolonged cultivation times of cell assays with BSE-H prions as compared to those 330 
with the 263K- or 22A-H scrapie agents.  331 
 332 
Quantitative PMCA assay for the titration of 263K scrapie seeding activity  333 
in vitro 334 
In order to facilitate quantitative PMCA, we simplified a PMCA assay previously 335 
established in our laboratory,15 and adapted it to rapid end-point titration of prion 336 
seeding activity. Figure 3 shows that PrPres amplification could be detected after two 337 
rounds of PMCA when 1x10-11 g or higher amounts of 263K stock were used for 338 
seeding, while 1x10-12 g 263K stock produced negative results in this PMCA series. 339 
In unseeded PMCA batches no PrPres amplification was detected (not shown). 340 
We used the data from these and  similar PMCA experiments for an SD50 341 
assessment. PMCA with 1x10-9, 1x10-10, 1x10-11 or 1x10-12 g 263K stock (n=10 each) 342 
produced detectable PrPres amplification in 10/10, 10/10, 9/10 and 2/10 samples, 343 
respectively, and indicated that 1x10-13 g 263K stock would consistently deliver 344 
negative results after two rounds of PMCA. Spearman-Kärber analysis performed on 345 
this basis revealed that 1.0x10-11.6 g (standard deviation: 0.6 logarithmic10 units) of 346 
the 263K stock (from previous titrations in hamster bioassays estimated to carry 347 
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about 3x10-3 intracerebral ID50) contained one SD50 in our PMCA assay after two 348 
amplification rounds.  349 
In the light of these results we suggest the following simple standard procedure for 350 
the end-point titration of unknown SD50 titres in 263K scrapie samples by quantitative 351 
PMCA: 352 
Test PMCA batches are seeded, at least in duplicate, with aliquots of serially tenfold 353 
100 – 10-12-diluted samples of unknown 263K scrapie material. In parallel, reference 354 
PMCA batches for internal assay calibration are seeded with 1.0x10-10, 1.0x10-11, 355 
1.0x10-12, and 1.0x10-13 g 263K stock. The dilutions of the unknown test material and 356 
of the 263K stock that contain one SD50 each are calculated from the Western blot 357 
read-outs after two PMCA rounds by the method of Spearman-Kärber. On this basis, 358 
the concentration of seeding activity in the test material can be concluded and 359 
directly compared to that in the 263K stock. By using the correlation factor between 360 
SD50 and ID50 of the 263K stock, the seeding activities of test samples are tentatively 361 
translated into ID50 values. 362 
 363 
PMCA assays for other hamster-adapted scrapie- and BSE agents           364 
The highly efficient PMCA protocol established for the 263K scrapie agent was 365 
subsequently adapted to 22A-H- and BSE-H prions. For this purpose, we 366 
systematically examined the influence of the incubation time between the sonication 367 
steps, and of the concentration of EDTA in the conversion buffer, on the efficiency of 368 
PMCA with these TSE agents. This revealed that a robust amplification of PrPres 369 
could be achieved when both the EDTA concentration was elevated to 20 mM, and 370 
the incubation times were increased to 4 h or 2 h for 22A-H- and BSE-H prions, 371 
respectively (Figure 4). We found that 1.0x10-5 and 1.0x10-6 g of 22A-H- and BSE-H 372 
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stock effectively seeded, in a dose-dependent manner, the propagation of PrPres by 373 
PMCA.  374 
 375 
Quantitative PMCA assay for the titration of vCJD seeding activity on steel 376 
wires     377 
A further aim of our work was to adapt to human vCJD prions a previously described 378 
quantitative PMCA assay for the monitoring of 263K scrapie disinfection on 379 
surrogates for medical instruments.15 For this purpose, steel wires were 380 
contaminated with different amounts of vCJD prions, and brain homogenate from 381 
transgenic HuMM-mice served as PMCA substrate.   382 
As shown in Figure 5, PrPres amplification showed a consistent dependency from 383 
the dilution of the vCJD stock that has been used for the contamination of wires. 384 
Amplified PrPres could be detected after 5 to 8 PMCA rounds with wires that had 385 
been exposed to serially tenfold 10-2- to 10-5-diluted vCJD stock, respectively. In 386 
contrast, wires that had been coated with 10-6-diluted vCJD stock, or negative control 387 
wires not coated with vCJD stock, did not produce detectable PrPres amplification 388 
after up to 9 rounds of PMCA. A preliminary Spearman-Kärber analysis of our 389 
findings from so far two independently performed PMCA assessments indicated that 390 
wires contaminated with 10-5.5-diluted vCJD stock would carry one SD50 in our PMCA 391 
assay. Thus, we suggest the following procedure for the end-point titration of vCJD 392 
SD50 values on re-processed steel wires in disinfection studies:    393 
Test steel wires are incubated in 10-1-diluted  vCJD stock (and thereby contaminated 394 
with about 3x104 SD50). The test wires are then exposed to different disinfectants, 395 
and subsequently subjected to 9 rounds of PMCA. For internal assay calibration 396 
reference wires are contaminated with 10-4, 10-5 or 10-6-diluted vCJD stock and 397 
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subjected to PMCA without disinfection. The residual seeding activity remaining on 398 
the surface of re-processed test wires can be calculated from the PMCA read-outs by 399 
Spearman-Kärber analysis. By comparing the initial and residual seeding activities on 400 
test wires, the reduction factors achieved by different disinfection methods can be 401 
subsequently concluded over a range of slightly more than 4 logs.    402 
 403 
Discussion 404 
Quantitative cell assay for the titration of 263K scrapie infectivity in vitro 405 
To the best of our knowledge, this report presents for the first time a cell-based assay 406 
for the in vitro titration of 263K scrapie infectivity. Our cell assay for 263K scrapie 407 
titration is still about 100fold less sensitive than bioassays in hamsters (one CCID50 408 
corresponds to 100 ID50) and has a measuring range of 7 logs of infectivity. However, 409 
recently Arellano-Anaya reported that the sensitivity of assays using transgenic RK13 410 
cells for the detection of ovine or mouse scrapie prions was 100fold increased by two 411 
successive rounds of infection.16 If the sensitivity of our cell assay could be similarly 412 
enhanced by this approach, it would be on par with the hamster bioassay.           413 
Only two other cell culture models were previously found to be infectible with hamster 414 
scrapie prions.29,30 However, these cell assays were not used for the in vitro titration 415 
of scrapie infectivity and refer to a different hamster-adapted scrapie isolate, i. e. 416 
Sc237.31,32 While Sc237 and 263K prions have the same origin,33 they were 417 
ultimately obtained in distinct sets of passages and may thus differ in their properties. 418 
Findings by Kimberlin & Walker,34 as well as new evidence recently presented at the 419 
Prion 2012 Conference in Amsterdam,35,36 indicate that Sc237 and 263K are distinct 420 
hamster-adapted prion agents, and that other than the cloned 263K strain the Sc237 421 
isolate contains different substrains.    422 
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Cryo-storage and plate cultivation of glia allow efficient use of normal hamster brain 423 
tissue in the cell assay      424 
By the cryo-storage of ready-to-use glia cells and their cultivation in six well plates 425 
donor hamster brains can be better used for the preparation and supply of glia cells, 426 
and more cultures can be processed simultaneously, than with our previous cell 427 
culture protocol. 300 cell cultures (each to be kept in an individual plate well) can be 428 
produced from the stock of glia harvested from one neonatal hamster brain. 429 
For the titration of 263K scrapie infectivity in an unknown sample by hamster 430 
incubation time interval bioassays, usually 5 hamsters have to be inoculated (end-431 
point titrations would still require a substantially higher number of animals). In the cell 432 
assay described above for 263K scrapie prions, 24 glial cultures derived from normal 433 
hamster brain tissue and tiny amounts of 263K stock are required to determine the 434 
CCID50 of an unknown specimen in duplicate. If the internal assay calibration is 435 
performed in duplicate with 10-6, 10-7 or 10-8 g 263K stock, one brain from a scrapie 436 
hamster (weighing about 1 g) provides sufficient reference tissue for the titration of 437 
about 5x105 unknown samples in the cell assay. At the same time, the 300 cell 438 
cultures available from one normal hamster brain allow to determine the CCID50 of 439 
twelve 263K scrapie specimens in vitro. The titration of this number of samples in 440 
hamster incubation time interval bioassays would require inoculation of 60 animals. 441 
Thus, one normal hamster brain and slightly more than 2x10-6 g of a scrapie hamster 442 
brain optimally utilized in glial cell assays are theoretically sufficient to replace 263K 443 
scrapie bioassay titrations in 60 hamsters. 444 





Suitability of glial cell assays for infectivity titration of other hamster-adapted 448 
scrapie- and BSE agents 449 
In additional experiments we found that glial cell cultures were also susceptible to 450 
infection with 22A-H- and BSE-H prions. Infection of primary cells or cell lines with 451 
these laboratory TSE agents has not yet been reported to the best of our knowledge. 452 
We observed  a similar efficiency of cell infection by 263K- and 22A-H prions. For the 453 
BSE-H agent we found a lower, yet dose-dependent efficiency of infection that 454 
required higher doses of inoculum and a prolongation of the cultivation period. The 455 
threshold of infecting BSE-H- or 22A-H stock still causing detectable PrPres 456 
accumulation in glial cell cultures within a set number of days remains to be 457 
determined individually. With this information glial cell cultures can be directly used 458 
for the CCID50 titration of 22A-H- and BSE-H prions in a similar way as described for 459 
the 263K scrapie agent. When further pursuing this approach it should be also 460 
established whether the sensitivity of 22A-H- and BSE-H cell assays can be 461 
increased by successive rounds of infection. 462 
 463 
Quantitative PMCA assay for the titration of 263K scrapie seeding activity  464 
in vitro 465 
In order to facilitate the practical use of quantitative PMCA we here report an 466 
approach for the rapid end-point titration of 263K scrapie seeding activity by only two 467 
rounds of PMCA and simple Spearman-Kärber analysis of the assay read-outs. The 468 
rationale for such end-point titration of seeding activity was previously described by 469 
Wilham et al. in the context of RT-QuIC.14 Our method for the titration of 263K 470 
scrapie seeding activity by quantitative PMCA is about 300fold more sensitive than 471 
bioassays in hamsters (one SD50 corresponds to about 3x10
-3 intracerebral ID50) and 472 
23 
 
able to measure a range of seeding activity of more than 11 logs. With respect to the 473 
intrinsic variation of prion bioassay titrations our observed SD50/ID50 ratio is in good 474 
accordance with recently reported data from a study by Makarava et al. who found 475 
that one PMCA SD50  of their 263K stock corresponded to about 5-6x10
-3 476 
intracerebral ID50.
22 In this context it has to be noted that the 263K stock used by 477 
Makarava et al. showed about tenfold higher titers of both ID50 and SD50 in hamster- 478 
and PMCA assays, respectively, than our 263K stock.     479 
In our 2-round PMCA assay, 68 test- and reference PMCA batches, 34 of which each 480 
require an amount of about 150 μl or 120 μl 10% (w/v) normal hamster brain 481 
homogenate as PrPC substrate in the first and second PMCA round, respectively, 482 
have to be processed for the determination of the SD50 of an unknown specimen in 483 
duplicate. In this assay, one normal hamster brain and slightly more than 2x10-10 g 484 
263K stock are required to determine the 263K scrapie seeding activity of one 485 
unknown sample. A conventional hamster bioassays, in contrast, would usually 486 
require five animals for the sample´s titration.  487 
 488 
Suitability of PMCA assays for seeding activity titration of other hamster-489 
adapted scrapie- and BSE agents 490 
We have been able to establish in vitro assays for the seeding activity of BSE-H and 491 
22A-H prions that can be combined with a testing in the glial cell cultures described 492 
above. We are not aware of previous reports describing similar serial PMCA 493 
procedures for BSE-H or 22A-H. However, the feasibility of PMCA with 22A-H prions 494 
had been already previously established by Ayers et al. who demonstrated the 495 
amplification of 22A-H-associated PrPres after one round of PMCA.37       496 
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Although our PMCA assays for BSE-H- and 22A-H prions are less sensitive than the 497 
PMCA assay for 263K scrapie agent, in principle, they can be similarly used for an 498 
end-point titration of unknown SD50 titres. For this purpose only the minimum amount 499 
of BSE-H- or 22A-H stock that is just sufficient to induce detectable PrPres 500 
amplification after a set number of PMCA rounds remains to be determined 501 
individually. On this basis, the range of test sample dilutions suitable for SD50 end-502 
point titration and the reference amounts of BSE-H- and 22A-H stock needed for 503 
assay calibration can be easily adjusted in analogy to quantitative PMCA with the 504 
263K scrapie agent. 505 
 506 
Quantitative PMCA assay for the titration of vCJD seeding activity on steel 507 
wires    508 
Prions rank amongst the most tolerant pathogens in hierarchical scales of resistance 509 
to disinfection and place particularly high demands to the re-processing of medical 510 
devices.38 So far, bioassays in animals provide the gold standard for monitoring the 511 
disinfection of prions.39,40  512 
Recently, we were able to establish the proteinaceous seeding activity of 263K 513 
scrapie-associated PrPTSE as a highly sensitive quantitative indicator for the 514 
disinfection of 263K scrapie prions on steel wires used as surrogates for medical 515 
devices.15 However, the tolerance to individual disinfection methods may vary 516 
between distinct prion strains.41 We have therefore suggested to devise PMCA 517 
protocols for the sensitive quantification in vitro of sCJD and vCJD-associated 518 
seeding activity in disinfection studies. In this report we describe, to the best of our 519 
knowledge for the first time, such an assay for vCJD prions on steel wires. 520 
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There are no rodent models commonly available that would allow the sensitive 521 
titration of vCJD prions over a broad range of infectivity. Mouse strains frequently 522 
used for the detection of vCJD infectivity show long incubation periods upon primary 523 
passage of the agent from humans as reported for RIII (~300-400 days) and C57BL6 524 
mice.42 In a most recent vCJD inactivation study Fernie et al. observed incubation 525 
times of about 670 days in RIII mice that had been challenged with 10-4 dilutions of 526 
vCJD brain tissue.43 The range of infectivity measurement in the RIII mice of these 527 
study was 3 logs.  528 
As compared to such studies in RIII mice our PMCA assay would be substantially 529 
less time consuming and more sensitive, since it allows to monitor seeding activity 530 
reductions on steel wires of more than 4 logs. So far we have performed PMCA with 531 
vCJD-contaminated steel wires for up to 9 rounds in three independent test runs. A 532 
further increase in the number of rounds might improve the sensitivity of the assay 533 
and allow the detection of lower amounts of seeding activity. Thus, our SD50 estimate 534 
of vCJD-contaminated steel wires still requires further validation.       535 
According to our rationale, we are currently trying to establish a complementing cell 536 
assay for the in vitro titration of vCJD infectivity. Based on our findings with hamsters, 537 
glial cells from RIII mice would provide obvious candidates for this purpose. 538 
 539 
Conclusion and outlook 540 
In this paper we present a rationale and methodology for the progressive reduction 541 
and eventual replacement of prion bioassay titrations in laboratory rodents. This 542 
approach will also facilitate studies on the anti-prion effectiveness of (re-)processing 543 
procedures for medical devices and biological products, and help to further harness 544 
prions as test agents for the development of broad-range disinfectants and as bio-545 
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indicators for sterilization processes.37  However, in order to definitely prove that 546 
combinations of PMCA- and cell assays provide an effective or even superior 547 
alternative to bioassays in laboratory rodents, prion titre estimates from such jointly 548 
performed in vitro assays remain to be further validated by actual ID50 data from   549 
- preferably completed - in vivo studies.        550 
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Legends to Figures 659 
Figure 1. Glial cell assay for in vitro end-point titration of 263K scrapie 660 
infectivity. Western blot detection of PrPres, the PK-resistant core of misfolded PrP, 661 
at the indicated days post initial exposure (DPE) in glial cell cultures from hamsters 662 
that had been inoculated with normal hamster brain homogenate containing 0, 663 
2.5x10-5, 1.0x10-6, 1.0x10-7, or 1.0x10-8 g 263K stock. Cells were cultivated for three 664 
days with these inocula. Subsequently, the inocula were removed, and the cells were 665 
washed and further cultivated until cell harvesting. Lane R, PrPres blot standard: PK-666 
digested 263K stockcorresponding to  5x10-7 g brain tissue. Lanes DPE, 3.8 μl 667 
aliquots from resuspended cell culture pellets harvested either immediately after 668 
removal of the inoculum (i. e. at 3 DPE), or at 40 DPE. Western blot results from cell 669 
cultures infected with 2.5x10-5 and 1.0x10-6 g 263K stockwere reproduced under a 670 
creative commons license from previously published work.15 671 
 672 
Figure 2. PrPres accumulation in glial cell cultures challenged with 22A-H 673 
scrapie- or BSE-H prions. Western blot detection of PrPres at the indicated DPE in 674 
glial cell cultures from hamsters that had been inoculated with normal hamster brain 675 
homogenate containing 1.0x10-5 g 22A-H stock (A), or 0, 1.0 x 10-3, 1.0 x 10-4, or 1.0 676 
x 10-5 g  BSE-H stock (B). Cells were cultivated for three days with these inocula. 677 
Subsequently, the inocula were removed, and the cells were washed and further 678 
cultivated until cell harvesting. Lanes R, PrPres blot standard: PK-digested 263K 679 
stock corresponding to 5x10-7 g brain tissue. Lanes DPE, 3.8 μl aliquots from 680 
resuspended cell culture pellets harvested either immediately after removal of the 681 




Figure 3. PMCA assay for in vitro end-point titration of 263K scrapie-associated 684 
seeding activity. Western blot detection of PrPres after one or two rounds of PMCA 685 
seeded with 1x10-9, 1x10-10, 1x10-11, or 1x10-12 g 263K stock. Samples were run in 686 
duplicate, and sample lanes represent 4.2 μl-aliquots from the respective PMCA 687 
batches. Lanes R, PrPres blot standard: PK-digested 263K stock corresponding to 688 
5x10-7 g brain tissue each. The incubation time per PMCA cycle was 1 h. 689 
 690 
Figure 4. PMCA with 22A-H scrapie- or BSE-H prions. Western blot detection of 691 
PrPres after 0, 1, 2, 3 or 4 rounds of PMCA seeded with 1.0x10-5 or 1.0x10-6 g 22A-H 692 
stock(A), or with the same amounts of BSE-H stock(B). Sample lanes represent 4.2 693 
l-aliquots from PMCA batches. Lanes R, PrPres blot standard: PK-digested 22A-H- 694 
(A), or BSE-H stock (B) corresponding to 5x10-7 g or 1x10-6 g brain tissue, 695 
respectively. The incubation time per PMCA cycle was 4 h for 22A-H prions in (A), 696 
and 2h for BSE-H prions in (B).  697 
 698 
Figure 5. PMCA with vCJD prions on steel wires. Western blot detection of PrPres 699 
after PMCA seeded with steel wires that had been contaminated with the indicated 700 
dilutions of vCJD stock. Lanes R, PrPres blot standard: PK-digested 263K stock 701 
corresponding to 5x10-7 g brain tissue. Numbered lanes 1-9 represent 4.2 μl-aliquots 702 
from PMCA batches sampled after 1, 2, 3, 4, 5, 6, 7, 8, or 9 rounds of amplification. 703 
Negative control wires were subjected to PMCA in normal HuMM mouse brain 704 
homogenate  without prior contamination with vCJD stock. M, molecular mass 705 
indicator.   706 





